Drugs / DAROTROPIUM
DAROTROPIUM
also known as
GSK233705 · Bromure de darotropium · Bromuro de darotropio · DAROTROPIUM BROMIDE · Darotropium cation · Darotropium ion · GSK233705B
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00783003 | Nov 2008 → Feb 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00964405 | Sep → Dec 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00671216 | May → Jul 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00500461 | Jun → Jul 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00453687 | Mar → May 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00279019 | Dec 2005 → Jun 2006 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00749411 | Nov 2008 → Feb 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00676052 | May → Dec 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00453479 | Mar → Oct 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00422604 | Oct 2006 → May 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00376714 | Aug 2006 → Apr 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAROTROPIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | Bromure de darotropium | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | Bromuro de darotropio | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | DAROTROPIUM BROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | Darotropium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | Darotropium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL2365940 ↗ |
| Known as | GSK233705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00676052 ↗ |
| Known as | GSK233705B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00453479 ↗ |
| Action | Inhibit | “GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist” NCT00279019 ↗ |
| Modality | Small molecule | — CHEMBL2365940 ↗ |
| Route | Oral | “GSK233705 will be given orally” NCT00279019 ↗ |